STAT3 and cancer: Niclosamide, a specific inhibitor of STAT3, can negate the upregulation of MRP1 and MDR1 induced by MALAT1, highlighting the potential of targeting STAT3 to modulate drug resistance mediated by lncRNAs in cancer therapy [288].